These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 1700507)

  • 1. Inhibition of the metabolism of cyclosporine by human liver microsomes by FK506.
    Burke MD; Omar G; Thomson AW; Whiting RH
    Transplantation; 1990 Nov; 50(5):901-2. PubMed ID: 1700507
    [No Abstract]   [Full Text] [Related]  

  • 2. FK 506 inhibition of cyclosporine metabolism by human liver microsomes.
    Omar G; Shah IA; Thomson AW; Whiting PH; Burke MD
    Transplant Proc; 1991 Feb; 23(1 Pt 2):934-5. PubMed ID: 1703356
    [No Abstract]   [Full Text] [Related]  

  • 3. Isolation of an immunosuppressive metabolite of FK506 generated by human microsome preparations.
    Christians U; Radeke HH; Kownatzki R; Schiebel HM; Schottmann R; Sewing KF
    Clin Biochem; 1991 Jun; 24(3):271-5. PubMed ID: 1714802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and in vitro immunosuppressive activity of a SDZ-IMM-125 metabolite isolated from phenobarbital-induced rabbit liver microsomes.
    Dieden R; Verbeeck RK; Maton N; Latinne D; Lhoëst GJ
    Xenobiotica; 1997 Sep; 27(9):933-49. PubMed ID: 9381734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of twenty-three drugs on the metabolism of FK506 by human liver microsomes.
    Iwasaki K; Matsuda H; Nagase K; Shiraga T; Tokuma Y; Uchida K
    Res Commun Chem Pathol Pharmacol; 1993 Nov; 82(2):209-16. PubMed ID: 7508138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of the new immunosuppressive drug FK506 on the formation of secondary metabolites of cyclosporin A.
    Bauer S; Brockmöller J; Kewitz H; Roots I
    Int J Clin Pharmacol Ther Toxicol; 1992 Nov; 30(11):540-2. PubMed ID: 1283385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of FK506 versus cyclosporine on human natural and antibody-dependent cytotoxicity reactions in vitro.
    Wasik M; Gorski A; Stepien-Sopniewska B; Lagodzinski Z
    Transplantation; 1991 Jan; 51(1):268-70. PubMed ID: 1702910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the effects of FK506 and cyclosporine on bone mineral metabolism in the rat. A pilot study.
    Katz IA; Takizawa M; Jaffe II; Stein B; Fallon MD; Epstein S
    Transplantation; 1991 Sep; 52(3):571-4. PubMed ID: 1716801
    [No Abstract]   [Full Text] [Related]  

  • 9. Interactions of FK506 (tacrolimus) with clinically important drugs.
    Matsuda H; Iwasaki K; Shiraga T; Tozuka Z; Hata T; Guengerich FP
    Res Commun Mol Pathol Pharmacol; 1996 Jan; 91(1):57-64. PubMed ID: 8824931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased cyclosporine uptake by cells pretreated with FK506 and evidence for binding of both drugs to a common intracellular protein.
    Sanghvi A; Warty VS; Diven WF; Todo S; Starzl T
    Transplant Proc; 1989 Feb; 21(1 Pt 1):1050-2. PubMed ID: 2468204
    [No Abstract]   [Full Text] [Related]  

  • 11. Risk Assessment of Drug-Drug Interactions of Calcineurin Inhibitors Affecting Sirolimus Pharmacokinetics in Renal Transplant Patients.
    Emoto C; Vinks AA; Fukuda T
    Ther Drug Monit; 2016 Oct; 38(5):607-13. PubMed ID: 27310200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence that the immunosuppressive effects of FK506 and cyclosporine are identical.
    Johansson A; Möller E
    Transplantation; 1990 Dec; 50(6):1001-7. PubMed ID: 1701570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative study between cyclosporine and FK 506 effects on renal microsomal P-450.
    Yoshimura R; Yoshimura N; Kusunose E; Hamashima T; Ohsaka Y; Kusunose M; Oka T; Kishimoto T; Maekawa M
    Transplant Proc; 1991 Feb; 23(1 Pt 1):311-3. PubMed ID: 1703686
    [No Abstract]   [Full Text] [Related]  

  • 14. Inhibition of cyclosporine and tetrahydrocannabinol metabolism by cannabidiol in mouse and human microsomes.
    Jaeger W; Benet LZ; Bornheim LM
    Xenobiotica; 1996 Mar; 26(3):275-84. PubMed ID: 8730919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phospholipase-C and Na-K ATPase activation by cyclosporine and FK506 in LLC-PK1, cells. Possible implications in blood pressure regulation.
    Ellis D; Gabriel ME; Ellis MP
    Transplantation; 1991 Aug; 52(2):349-53. PubMed ID: 1714643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of cyclosporine metabolism by other drugs in vitro.
    Henricsson S; Lindholm A
    Transplant Proc; 1988 Apr; 20(2 Suppl 2):569-71. PubMed ID: 3284104
    [No Abstract]   [Full Text] [Related]  

  • 17. A comparison of in vivo responses to cyclosporine, FK506, and rapamycin following allogeneic immune challenge.
    Lorber MI; Wilson JH; Harding MW; Gromkowski S; Marks WH
    Transplantation; 1991 Jul; 52(1):167-70. PubMed ID: 1713364
    [No Abstract]   [Full Text] [Related]  

  • 18. Chemistry and biology of the immunophilins and their immunosuppressive ligands.
    Schreiber SL
    Science; 1991 Jan; 251(4991):283-7. PubMed ID: 1702904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Further metabolism of FK506 (tacrolimus). Identification and biological activities of the metabolites oxidized at multiple sites of FK506.
    Iwasaki K; Shiraga T; Matsuda H; Nagase K; Tokuma Y; Hata T; Fujii Y; Sakuma S; Fujitsu T; Fujikawa A
    Drug Metab Dispos; 1995 Jan; 23(1):28-34. PubMed ID: 7536652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the immunosuppressant FK-506 and its analog FK-520 on hepatic and renal cytochrome P450 mixed-function oxidase.
    Vincent SH; Wang RW; Karanam BV; Klimko M; Alvaro R; Chiu SH
    Biochem Pharmacol; 1991 May; 41(9):1325-30. PubMed ID: 1708254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.